<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341923</url>
  </required_header>
  <id_info>
    <org_study_id>CLJ369-P001</org_study_id>
    <nct_id>NCT03341923</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of DAILIES TOTAL 1® Multifocal Compared to 1-Day Acuvue® Moist® Multifocal in a Japanese Population</brief_title>
  <official_title>Clinical Evaluation of DAILIES TOTAL 1® Multifocal Compared to 1-Day Acuvue® Moist® Multifocal in a Japanese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate DAILIES TOTAL1® Multifocal (DT1MF) contact
      lenses compared to 1-DAY ACUVUE® Moist® Multifocal (AMMF) contact lenses for
      investigator-graded lens centration in a Japanese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomly assigned to one of two sequences of investigational product wear
      ((DT1MF→AMMF, AMMF→DT1MF). Each product will be worn in both eyes for at least 11 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">June 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Investigator-graded Lens Centration of &quot;Optimal&quot;</measure>
    <time_frame>Day 14, each product</time_frame>
    <description>Lens centration was assessed by slit-lamp microscopy and graded on a 5-point scale, where 0=Optimal/Centered and 4=Severe decentration (with corneal exposure). One target eye was randomly selected for analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Refractive Error</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>DT1MF, then AMMF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMMF, then DT1MF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A multifocal contact lenses</intervention_name>
    <description>Silicone hydrogel multifocal contact lenses for daily disposable wear</description>
    <arm_group_label>AMMF, then DT1MF</arm_group_label>
    <arm_group_label>DT1MF, then AMMF</arm_group_label>
    <other_name>DAILIES TOTAL 1® Multifocal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etafilcon A multifocal contact lenses</intervention_name>
    <description>Hydrogel multifocal contact lenses for daily disposable wear</description>
    <arm_group_label>AMMF, then DT1MF</arm_group_label>
    <arm_group_label>DT1MF, then AMMF</arm_group_label>
    <other_name>1-DAY ACUVUE® Moist® Multifocal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign informed consent

          -  Habitually wear multifocal soft/ silicone hydrogel contact lenses

          -  Require a near spectacle ADD of +0.50 diopters (D) to +2.50D (inclusive)

          -  Correctable to 20/30 Snellen or 0.2 logarithm minimum angle of resolution (logMAR) or
             better in each eye at distance

          -  Willing to wear contact lenses and attend all study visits

        Exclusion Criteria:

          -  Currently wearing DAILIES TOTAL 1® Multifocal or 1-DAY ACUVUE® Moist® Multifocal
             contact lenses

          -  Any eye condition that would make contact lens wear unadvisable

          -  Any use of medication that would make contact lens wear unadvisable

          -  Prior refractive surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Koto-Ku</city>
        <state>Tokyo</state>
        <zip>136-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <zip>164-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Shinagawa-Ku</city>
        <state>Tokyo</state>
        <zip>141-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Taitō</city>
        <state>Tokyo</state>
        <zip>110-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=17405</url>
    <description>Results from the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <results_first_submitted>March 26, 2019</results_first_submitted>
  <results_first_submitted_qc>March 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact lenses</keyword>
  <keyword>lens centration</keyword>
  <keyword>multifocal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03341923/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03341923/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 4 study sites located in Japan.</recruitment_details>
      <pre_assignment_details>Of the 151 enrolled, 17 subjects were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (134).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DT1MF, Then AMMF</title>
          <description>Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.</description>
        </group>
        <group group_id="P2">
          <title>AMMF, Then DT1MF</title>
          <description>Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, First 14 Days of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, Second 14 Days of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="66">Subject completed Period 1 but was discontinued before starting Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all subjects who used the investigational medical devices and provided data after the use. The lenses used at Visit 1 (baseline) for the selection of parameters are not regarded as investigational medical devices (Full Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Delefilcon A multifocal contact lenses and etafilcon A multifocal contact lenses worn during Period 1 and Period 2 in a crossover assignment, as randomized.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Investigator-graded Lens Centration of &quot;Optimal&quot;</title>
        <description>Lens centration was assessed by slit-lamp microscopy and graded on a 5-point scale, where 0=Optimal/Centered and 4=Severe decentration (with corneal exposure). One target eye was randomly selected for analysis.</description>
        <time_frame>Day 14, each product</time_frame>
        <population>Full Analysis Set with data available</population>
        <group_list>
          <group group_id="O1">
            <title>DT1MF</title>
            <description>Delefilcon A multifocal contact lenses worn binocularly during Period 1 or Period 2 for 14 +/- 3 days, as randomized.</description>
          </group>
          <group group_id="O2">
            <title>AMMF</title>
            <description>Etafilcon A multifocal contact lenses worn binocularly during Period 1 or Period 2 for 14 +/- 3 days, as randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Investigator-graded Lens Centration of &quot;Optimal&quot;</title>
          <description>Lens centration was assessed by slit-lamp microscopy and graded on a 5-point scale, where 0=Optimal/Centered and 4=Severe decentration (with corneal exposure). One target eye was randomly selected for analysis.</description>
          <population>Full Analysis Set with data available</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0"/>
                    <measurement group_id="O2" value="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Difference (DT1MF-AMMF) of percentage of subjects rated as “Optimal” was provided with two-sided 95% confidence interval (CI). If lower limit of CI was above -10% as non-inferiority criteria, non-inferiority was to be demonstrated.</non_inferiority_desc>
            <p_value>0.0455</p_value>
            <method>McNemar</method>
            <param_type>Difference in proportion</param_type>
            <param_value>6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>After demonstrating noninferiority, if lower limit of CI was above 0% as superiority criteria, superiority was to be demonstrated.</non_inferiority_desc>
            <p_value>0.0455</p_value>
            <method>McNemar</method>
            <param_type>Difference in proportion</param_type>
            <param_value>6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through study completion, an average of 28 days</time_frame>
      <desc>Safety was assessed at each visit. This analysis population includes all data of subjects who used the investigational medical devices. Lenses used at Visit 1 (baseline) for the selection of parameters are not regarded as investigational medical devices (Safety Analysis Set, based on treatment-specific exposure). “At Risk&quot; population for ocular Adverse Events is included with unit of “eyes.&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>DT1MF Ocular</title>
          <description>Eyes exposed to delefilcon A multifocal contact lenses</description>
        </group>
        <group group_id="E2">
          <title>DT1MF Systemic</title>
          <description>Subjects exposed to delefilcon A multifocal contact lenses</description>
        </group>
        <group group_id="E3">
          <title>AMMF Ocular</title>
          <description>Eyes exposed to etafilcon A multifocal contact lenses</description>
        </group>
        <group group_id="E4">
          <title>AMMF Systemic</title>
          <description>Subjects exposed to etafilcon A multifocal contact lenses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Group Manager, Vision Care</name_or_title>
      <organization>Alcon Japan, Ltd.</organization>
      <phone>+81.3.6899.5061</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

